Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,809 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,163 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00301756 | Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2018 | clinicaltrials |
| NCT01815515 | Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 |
| Aug 20, 2018 |
| clinicaltrials |
| NCT00004149 | Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy | completed | Phase 2 | 37 | Albert Einstein College of MedicineOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT02107950 | Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma | completed | Phase 2 | 71 | SOTIO a.s.INDUSTRY | 3 | Aug 15, 2018 | clinicaltrials |
| NCT00230542 | Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer | completed | Phase 2 | 44 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT00002943 | Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer | completed | Phase 2 | 11 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00345813 | Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer | completed | Phase 2 | 62 | Wake Forest University Health SciencesOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT01260688 | Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 2 | Aug 8, 2018 | clinicaltrials |
| NCT00223665 | Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer(IAS) | completed | Phase 2 | 102 | University of WashingtonOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT00283803 | Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer | completed | Phase 2 | 32 | University of WashingtonOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT00039624 | Magnetic Resonance-Guided High-Dose Brachytherapy (Short-Range Radiation Therapy) for Prostate Cancer | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Aug 2, 2018 | clinicaltrials |
| NCT01656304 | Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 16 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 31, 2018 | clinicaltrials |
| NCT00520013 | Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors | completed | Phase 2 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT00114166 | Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 81 | Gynecologic Oncology GroupNETWORK | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00699907 | Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer | completed | Phase 2 | 127 | University of ArizonaOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00867503 | Open Trial of Bendamustine Hydrochloride in Women With Advanced Ovarian Cancer | completed | Phase 2 | 10 | University of ArizonaOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT00121173 | Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia | completed | Phase 1 / Phase 2 | 16 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00520481 | Study With IMC-A12 (Cixutumumab) in Patients Who Have Not Previously Been Treated With Chemotherapy With Metastatic Prostate Cancer | completed | Phase 2 | 41 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 19, 2018 | clinicaltrials |
| NCT00459290 | Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 24 | Gynecologic Oncology GroupNETWORK | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00569673 | Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer | completed | Phase 2 | 71 | Gynecologic Oncology GroupNETWORK | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01045109 | Vitamin D3 Supplementation in Participants Diagnosed With Early-Stage Prostate Cancer Who Decide to Undergo Active Surveillance Treatment Regimen.(D3/PCa) | completed | Phase 2 | 52 | Medical University of South CarolinaOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01824615 | Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma | completed | Phase 2 | 30 | Cathay General HospitalOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01054079 | Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01553539 | Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery | completed | Phase 2 | 20 | Wake Forest University Health SciencesOTHER | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01652079 | CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer | completed | Phase 2 | 63 | Massachusetts General HospitalOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00659360 | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 2 | Jun 29, 2018 | clinicaltrials |
| NCT00272038 | Single Agent Erlotinib in Chemotherapy-naive Androgen Independent Prostate Cancer | completed | Phase 2 | 29 | Oncology Specialists, S.C.OTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT02948075 | Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | completed | Phase 2 | 31 | NewVac LLCINDUSTRY | 1 | Jun 27, 2018 | clinicaltrials |
| NCT00165399 | Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment | completed | Phase 2 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 25, 2018 | clinicaltrials |
| NCT00228319 | Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants | completed | Phase 1 / Phase 2 | 27 | Jeanne Drisko, MD, CNS, FACNOTHER | 1 | Jun 19, 2018 | clinicaltrials |
| NCT01867086 | Salvage Ovarian FANG™ Vaccine + Carboplatinum | completed | Phase 2 | 1 | Gradalis, Inc.INDUSTRY | 1 | Jun 19, 2018 | clinicaltrials |
| NCT00090545 | A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2018 | clinicaltrials |
| NCT02340611 | A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib | completed | Phase 2 | 4 | University Health Network, TorontoOTHER | 1 | Jun 12, 2018 | clinicaltrials |
| NCT01220973 | Atorvastatin Calcium and Celecoxib in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer | completed | Phase 2 | 27 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 8, 2018 | clinicaltrials |
| NCT01113957 | A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer | completed | Phase 2 | 168 | AbbVie (prior sponsor, Abbott)INDUSTRY | 8 | Jun 6, 2018 | clinicaltrials |
| NCT01521949 | Study of Acai Juice in Asymptomatic or Minimally Symptomatic Prostate Cancer Patients With Rising PSA | completed | Phase 2 | 21 | University of Colorado, DenverOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01091428 | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | completed | Phase 2 | 191 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT01764802 | Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer | completed | Phase 2 | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | May 30, 2018 | clinicaltrials |
| NCT01620593 | Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer | completed | Phase 2 | 41 | The University of Texas Health Science Center at San AntonioOTHER | 1 | May 23, 2018 | clinicaltrials |
| NCT01090765 | A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | May 22, 2018 | clinicaltrials |
| NCT00075569 | SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia | completed | Phase 2 | 64 | Albert Einstein College of MedicineOTHER | 1 | May 21, 2018 | clinicaltrials |
| NCT00006101 | Eflornithine in Treating Patients At High Risk of Developing Prostate Cancer | completed | Phase 2 | 76 | Thomas E. AhleringOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT02083185 | A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer | completed | Phase 2 | 136 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | May 9, 2018 | clinicaltrials |
| NCT02130700 | Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer | completed | Phase 2 | 17 | Innocrin PharmaceuticalINDUSTRY | 1 | May 7, 2018 | clinicaltrials |
| NCT00428610 | A Study of Chemotherapy Treatment for Patients With Ovarian Cancer | completed | Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 3 | Apr 19, 2018 | clinicaltrials |
| NCT00513071 | AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 28 | National Cancer Institute (NCI)NIH | 1 | Apr 19, 2018 | clinicaltrials |
| NCT01644825 | Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer(MITO-11) | completed | Phase 2 | 72 | National Cancer Institute, NaplesOTHER | 1 | Apr 9, 2018 | clinicaltrials |
| NCT00483327 | Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate | completed | Phase 2 | 31 | NYU Langone HealthOTHER | 1 | Apr 4, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Aug 20, 2018source: clinicaltrials